RISULTATI DEL TRATTAMENTO PROLUNGATO DEL MORBO DI PARKINSON CON L'ASSOCIAZIONE L DOPA + BENSERAZIDE

The reasons why treatment of Parkinson's disease with the combination L Dopa+decarboxylase inhibitor ('Benserazide') is better than with L Dopa alone are presented. Experimental and clinical results obtained by other authors with this combination drug are extensively reported. Observations on the treatment of 45 Parkinsonian patients with 'Madopar' (L Dopat 'Benserazide') for a period up to 3 yr are reported. Thirty seven patients had a moderate to good improvement in their symptomatology, 8 other patients showed a slight response to the treatment. An appreciable improvement was shown in tremor, which was scarcely influenced by L Dopa alone. A satisfactory stability of the therapeutic effectiveness was observed during 3 yr. 'Peripheral' side effects were minimized by the combination drug, 'central' side effects were only slightly less frequent in comparison with those reported with L Dopa alone.